Delving into the Latest Updates on 青岛东海药业有限公司 with Synapse

概览

排名前五的药物类型	数量

益生菌	2

关联

2

项与青岛东海药业有限公司相关的药物

Bacillus coagulans(Qingdao Eastsea Pharmaceutical)

凝结芽孢杆菌活菌(青岛东海药业)

靶点-

作用机制

细菌替代物 [+1]

在研机构

青岛东海药业有限公司

原研机构

青岛东海药业有限公司

在研适应症

菌群失调

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2005-01-01

Clostridium butyricum(Qingdao Eastsea Pharma)

酪酸梭菌活菌 (青岛东海药业)

靶点-

作用机制

细菌替代物 [+1]

在研机构

青岛东海药业有限公司

原研机构

青岛东海药业有限公司

在研适应症

溃疡性结肠炎 [+4]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2004-11-26

1

项与青岛东海药业有限公司相关的临床试验

NCT02614963 / Unknown status临床4期IIT

Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome: A Randomized, Double-blinded,Placebo- Controlled Multicenter Study

Clostridium Butyricum might be an effective drug in treating irritable bowel syndrome

开始日期2015-12-01

申办/合作机构

山东大学

[+2]

100 项与青岛东海药业有限公司相关的临床结果

登录后查看更多信息

0 项与青岛东海药业有限公司相关的专利（医药）

登录后查看更多信息

1

项与青岛东海药业有限公司相关的文献（医药）

2023-01-01·Frontiers in immunology

Combination of thalidomide and Clostridium butyricum relieves chemotherapy-induced nausea and vomiting via gut microbiota and vagus nerve activity modulation.

Article

作者: Wu, Heng ; Wei, Hong ; Wei, Jing ; Zhu, Ruizhe ; Shang, Gaishuang ; Chen, Tingtao ; Tian, Puyuan ; Zhao, Xuanqi ; Shang, Haitao

Nausea and vomiting (CINV) are distressful and widespread side effects of chemotherapy, and additional efficient regimens to alleviate CINV are urgently needed. In the present study, colorectal cancer (CRC) mice model induced by Azoxymethane (AOM)/Dextran Sodium Sulfate (DSS) was employed to evaluate the cancer suppression and CINV amelioration effect of the combination of thalidomide (THD) and Clostridium butyricum. Our results suggested that the combination of THD and C. butyricum abundantly enhanced the anticancer effect of cisplatin via activating the caspase-3 apoptosis pathway, and also ameliorated CINV via inhibiting the neurotransmitter (e.g., 5-HT and tachykinin 1) and its receptor (e.g., 5-HT₃R and NK-1R) in brain and colon. Additionally, the combination of THD and C. butyricum reversed the gut dysbacteriosis in CRC mice by increasing the abundance of Clostridium, Lactobacillus, Bifidobacterium, and Ruminococcus at the genus level, and also led to increased expression of occludin and Trek1 in the colon, while decreased expression of TLR4, MyD88, NF-κB, and HDAC1, as well as the mRNA level of IL-6, IL-1β, and TNF-α. In all, these results suggest that the combination of THD and C. butyricum had good efficacy in enhancing cancer treatments and ameliorating CINV, which thus provides a more effective strategy for the treatment of CRC.

100 项与青岛东海药业有限公司相关的药物交易

登录后查看更多信息

100 项与青岛东海药业有限公司相关的转化医学

登录后查看更多信息